ATAI Life Sciences NV is a clinical-stage biopharmaceutical company that focuses on developing innovative treatments for mental health disorders. The company was founded in 2018 and is based in Amsterdam, the Netherlands.
ATAI is dedicated to developing treatments for mental health disorders that are not well addressed by existing therapies. The company's drug development pipeline includes a number of compounds that target conditions such as depression, anxiety, addiction, and post-traumatic stress disorder (PTSD).
The company's approach is to identify and develop promising drug candidates, and then partner with leading academic institutions and industry experts to conduct clinical trials and bring these treatments to market. In addition to drug development, ATAI also invests in digital therapeutics and other technologies that can help improve mental health outcomes.
ATAI has several partnerships with academic institutions and other companies to advance its drug development programs. The company's investors include some of the world's leading biotech and tech investors, including Peter Thiel's Founders Fund and Mike Novogratz's Galaxy Digital.
ATAI is publicly traded on the NASDAQ stock exchange under the ticker symbol "ATAI". As of May 2023, the company has a market capitalization of approximately $6.5 billion.
- Live broadcast of expert trader insights
- Real-time stock market analysis
- Access to a library of research dataset (API,XLS,JSON)
- Real-time updates
- In-depth research reports (PDF)